特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
969598

RNA解析/トランスクリプトミクスの世界市場・COVID-19の影響 (~2025年):製品 (試薬・機器・ソフトウェア)・技術 (マイクロアレイ・NGS・サンガー)・用途 (臨床診断・創薬)・エンドユーザー (CRO・病院)・地域別

RNA Analysis/ Transcriptomics Market by Product (Reagents, Instruments, Software), Technology (Microarrays, NGS, Sanger), Application (Clinical Diagnostics, Drug Discovery), End User (CROs, Hospitals), COVID-19 Impact - Global Forecast to 2025

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 194 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
RNA解析/トランスクリプトミクスの世界市場・COVID-19の影響 (~2025年):製品 (試薬・機器・ソフトウェア)・技術 (マイクロアレイ・NGS・サンガー)・用途 (臨床診断・創薬)・エンドユーザー (CRO・病院)・地域別
出版日: 2020年11月05日
発行: MarketsandMarkets
ページ情報: 英文 194 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

RNA解析/トランスクリプトミクスの市場規模は予測期間中13.9%のCAGRで推移し、2020年の45億米ドルから、2025年には87億米ドルの規模に成長すると予測されています。個別化医療への需要の増加、製薬・バイオテクノロジー分野のR&D費およびオミクス研究に対する政府資金の提供拡大、トランスクリプトミクス市場におけるRNAシーケンシングの導入拡大などの要因が同市場の成長を推進しています。また、バイオマーカーの発見、トキシコゲノミクスへの注目の高まり、アウトソーシングサービスへの関心の高まりなどの要因も参入事業者に大きな成長機会を示すと予測されています。

製品・サービス区分別で見ると、試薬/消耗品の部門が予測期間中最大のシェアを示すと予測されています。高品質の試薬に対する需要の高まり、トランスクリプトーム研究における培地、試薬の繰り返しの使用などの要因が同部門の成長を牽引しています。また、製薬業界でのR&D活動の拡大、ライフサイエンス研究への政府投資の拡大、統合オミクス研究の増加などの要因も消耗品部門の成長に貢献しています。

当レポートでは、世界のRNA解析/トランスクリプトミクスの市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、製品&サービス・技術・用途・エンドユーザー・産業・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題

第6章 産業考察

  • 産業動向
  • 戦略的ベンチマーク
  • ポーターのファイブフォース分析
  • 関連市場の分析
  • COVID-19の影響

第7章 市場分析・予測:製品・サービス別

  • 試薬・消耗品
  • 機器
  • ソフトウェア
  • サービス

第8章 市場分析・予測:技術別

  • ポリメラーゼ連鎖反応
  • シーケンシング
  • マイクロアレイ
  • RNA干渉(遺伝子サイレンシング)

第9章 市場分析・予測:用途別

  • 創薬
  • 臨床診断
  • トキシコゲノミクス
  • 比較トランスクリプトミクス

第10章 市場分析・予測:エンドユーザー別

  • 製薬・バイオテクノロジー企業
  • 病院・診断センター
  • 学術機関・研究機関
  • CRO

第11章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スイス
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • その他
  • ラテンアメリカ
  • 中東・アフリカ

第12章 競合情勢

  • 概要
  • 市場シェア分析
  • 企業評価マトリックス
  • 競合状況・動向

第13章 企業プロファイル

  • THERMO FISHER SCIENTIFIC, INC.
  • AGILENT TECHNOLOGIES, INC.
  • BIO-RAD LABORATORIES, INC.
  • CD GENOMICS
  • PROMEGA CORPORATION
  • ILLUMINA, INC.
  • QIAGEN N.V.
  • DANAHER CORPORATION
  • F. HOFFMANN-LA ROCHE LTD.
  • MERCK KGAA
  • FLUIDIGM CORPORATION
  • EUROFINS SCIENTIFIC
  • SEQUENTIA BIOTECH SL
  • ACOBIOM
  • GENXPRO GMBH
  • 他の有力企業
    • LEXOGEN GMBH
    • CENIX BIOSCIENCE GMBH
    • TAKARA HOLDINGS, INC.
    • BIOMERIEUX SA
    • LC SCIENCES, LLC

第14章 付録

目次
Product Code: BT 2766

The RNA analysis/transcriptomics market is projected to reach USD 8.7 billion by 2025 from USD 4.5 billion in 2020, at a CAGR of 13.9% during the forecast period. The growth of this market is majorly driven by the increasing demand for personalized medicine, increasing pharmaceutical and biotechnology R&D expenditure and government funding for omics, and the increasing applications of RNA sequencing in the transcriptomics market. The increasing focus on biomarker discovery and toxicogenomics, along with the increasing interest in outsourcing services, is expected to offer significant growth opportunities for the players operating in the global RNA analysis/transcriptomics market. On the other hand, the requirement of high capital investments and data management issues are expected to restrain the growth of this market to a certain extent.

Based on product, the reagents/consumables segment holds the largest market share during the forecast period.

Based on product & service, the RNA analysis/Transcriptomics market is segmented into reagents/consumables, instruments, software, and services. The reagents/consumables segment accounted for the larger market share in 2019. The increasing demand for high-quality reagents and the repeated use of media and reagents in transcriptome studies. Additionally, the growing R&D activities in the pharmaceutical industry, growing government investments in the field of life science research, and the increasing research being undertaken with integrated omics studies are contributing to the market for consumables.

Based on technology, the sequencing technologies segment is expected to register the highest CAGR during the forecast period.

Based on technology, the RNA analysis/transcriptomics market is segmented into microarrays, PCR, sequencing technologies (Sanger sequencing and NGS technologies), and RNAi (gene silencing). The sequencing technologies segment is expected to witness the highest growth during the forecast period. RNA sequencing allows direct access to sequences of mRNA and is an equitable technology, which makes it more suitable for target identification and drug discovery applications. RNA sequencing also helps to overcome several issues associated with microarrays, such as bias and variation due to hybridization and labeling efficiencies. Technological advancements in this segment are further set to drive market growth.

The drug discovery segment is expected to account for the largest share of the RNA analysis/transcriptomics market in 2019

The drug discovery segment accounted for the largest share of the market in 2019. This is attributed to the use of transcriptomics in drug discovery for target identification and validation, identification of efficacy and toxicity biomarkers from biological fluids, and investigation of drug action and toxicity mechanisms. The growing need to study a large number of genes to gain a better understanding of gene-to-drug interactions is further expected to drive the use of transcriptomic technologies in drug discovery applications.

CROs end user segment is expected to grow at the highest CAGR in the RNA analysis/transcriptomics market during the forecast period

Based on end user, the RNA analysis/transcriptomics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & diagnostic centers, and contract research organizations. The contract research organizations (CROs) segment is expected to witness the highest growth during the forecast period. CROs provide affordable outlets for companies and academia to pursue new medicines and offer a cost-effective solution to developing drugs. They also support foundations, research institutions, and universities, in addition to government organizations, such as the NIH and EMA. These factors are driving the growth of this segment.

North America is expected to account for the largest share of the RNA analysis/transcriptomics market in 2019

In 2019, North America accounted for the largest share of the RNA analysis/transcriptomics market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of this market segment can be attributed to the increasing development of structure-based drug designs, growing academic and government investments in genomics and proteomics research, high life science research funding, high biopharmaceutical R&D expenditure, and the greater adoption of advanced technologies in North America. The presence of a large number of global players in this region is another key factor contributing to the large share of this market segment.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-35%, Tier 2-5%, and Tier 3-20%
  • By Designation - C-level-35%, Director-level-25%, Others-40%
  • By Region - North America-45%, Europe-30%, Asia Pacific-20%, Latin America- 3%, Middle East and Africa-2%

Key players in the RNA analysis/transcriptomics market

The key players operating in the RNA analysis/transcriptomics market include: Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Fluidigm Corporation (US), Eurofins Scientific (Germany), Sequentia Biotech SL (Spain), Acobiom (France), GenXPro GmbH (Germany), CD Genomics (US), Promega Corporation (US), Lexogen GmbH (Austria), Cenix BioScience GmbH (Germany), Takara Holdings, Inc. (Japan), bioMerieux SA (France), and LC Sciences LLC (US).

Research Coverage:

The report analyzes the RNA analysis/transcriptomics market and aims at estimating the market size and future growth potential of this market based on various segments such as product, technology, application, end user, and region. The report also includes a product portfolio matrix of various RNA analysis/transcriptomics products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global RNA analysis/transcriptomics market. The report analyzes this market by product, technology, application, and end user
  • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global RNA analysis/transcriptomics market
  • Market Development: Comprehensive information on the lucrative emerging markets by product, technology, application, and end user
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global RNA analysis/transcriptomics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global RNA analysis/transcriptomics market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION & SCOPE
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
    • 1.2.2 MARKETS COVERED
    • FIGURE 1 RNA ANALYSIS/TRANSCRIPTOMICS MARKET
    • 1.2.3 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 STAKEHOLDERS
  • 1.5 LIMITATIONS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
    • FIGURE 3 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Breakdown of primaries
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 SEGMENTAL SHARE ANALYSIS ILLUSTRATION
    • FIGURE 6 TOP-DOWN APPROACH
  • 2.3 DATA TRIANGULATION APPROACH
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 8 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2020 VS. 2025 (USD MILLION)
    • FIGURE 9 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD MILLION)
    • FIGURE 10 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
    • FIGURE 11 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
    • FIGURE 12 GEOGRAPHIC ANALYSIS: RNA ANALYSIS/TRANSCRIPTOMICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 RNA ANALYSIS/TRANSCRIPTOMICS MARKET OVERVIEW
    • FIGURE 13 INCREASING RESEARCH BEING CONDUCTED USING OMICS TECHNOLOGIES TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY
    • FIGURE 14 PCR SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET IN 2019
  • 4.3 RNA ANALYSIS/TRANSCRIPTOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 15 MARKET IN CHINA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • 4.4 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY REGION (2018-2025)
    • FIGURE 16 NORTH AMERICA WILL CONTINUE TO DOMINATE THE RNA ANALYSIS/TRANSCRIPTOMICS MARKET UNTIL 2025
  • 4.5 RNA ANALYSIS/TRANSCRIPTOMICS MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 17 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • TABLE 1 RNA ANALYSIS/TRANSCRIPTOMICS MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing demand for personalized medicine
    • FIGURE 18 LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2016
      • 5.2.1.2 Increasing pharmaceutical and biotechnology R&D expenditure and government funding
    • FIGURE 19 R&D INVESTMENTS, BY COUNTRY, 2017 VS. 2018 (USD BILLION)
      • 5.2.1.3 Growing applications of RNA sequencing in transcriptomics
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High capital investments
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High growth opportunities in emerging markets
      • 5.2.3.2 Increasing application of toxicogenomics
      • 5.2.3.3 Increasing focus on biomarker discovery
      • 5.2.3.4 Rising focus on outsourcing
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Data management in transcriptomics research
      • 5.2.4.2 Lack of effective bioinformatics tools
      • 5.2.4.3 Dearth of skilled professionals

6 INDUSTRY INSIGHTS

  • 6.1 INTRODUCTION
  • 6.2 INDUSTRY TRENDS
    • 6.2.1 INTEGRATION OF OMICS DATA IN BIOMEDICAL SCIENCES
    • 6.2.2 GROWING FOCUS ON MONITORING POST-TRANSLATIONAL MODIFICATIONS
    • 6.2.3 SHIFT FROM PLANT-BASED TO GENOME-BASED DRUG DISCOVERY
    • 6.2.4 SPATIALLY RESOLVED TRANSCRIPTOMES
  • 6.3 STRATEGIC BENCHMARKING
    • TABLE 2 PRODUCT PORTFOLIO ANALYSIS: RNA ANALYSIS/TRANSCRIPTOMICS MARKET
  • 6.4 PORTER'S FIVE FORCES ANALYSIS
    • 6.4.1 THREAT OF NEW ENTRANTS
    • 6.4.2 THREAT OF SUBSTITUTES
    • 6.4.3 BARGAINING POWER OF BUYERS
    • 6.4.4 BARGAINING POWER OF SUPPLIERS
    • 6.4.5 INTENSITY OF COMPETITIVE RIVALRY
  • 6.5 RELATED MARKET ANALYSIS
  • 6.6 COVID-19 IMPACT ON THE RNA ANALYSIS/TRANSCRIPTOMICS MARKET

7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE

  • 7.1 INTRODUCTION
    • TABLE 3 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
  • 7.2 REAGENTS/CONSUMABLES
    • 7.2.1 REAGENTS/CONSUMABLES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    • TABLE 4 RNA ANALYSIS/TRANSCRIPTOMICS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.3 INSTRUMENTS
    • 7.3.1 THE NEED FOR ACCURATE ANALYSIS IS DRIVING THE ADOPTION OF AUTOMATED INSTRUMENTS
    • TABLE 5 RNA ANALYSIS/TRANSCRIPTOMICS INSTRUMENTS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.4 SOFTWARE
    • 7.4.1 NEED FOR DATA MANAGEMENT AND QUALITY ENHANCEMENTS OF RESULTS OBTAINED MAKES SOFTWARE SOLUTIONS AN IMPERATIVE PART OF TRANSCRIPTOMICS
    • TABLE 6 RNA ANALYSIS/TRANSCRIPTOMICS SOFTWARE MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.5 SERVICES
    • 7.5.1 INCREASING OUTSOURCING OF SERVICES TO PROPEL MARKET GROWTH
    • TABLE 7 RNA ANALYSIS/TRANSCRIPTOMICS SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)

8 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 8 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • 8.2 POLYMERASE CHAIN REACTION
    • 8.2.1 REAL-TIME PCR AIDS IN THE QUANTIFICATION OF LOW-COPY TRANSCRIPTS
    • TABLE 9 RNA ANALYSIS/TRANSCRIPTOMICS PCR MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 8.3 SEQUENCING
    • 8.3.1 ADVANCES IN NGS MULTIPLEXING CAPABILITIES TO AID MARKET GROWTH
    • TABLE 10 RNA ANALYSIS/TRANSCRIPTOMICS SEQUENCING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 8.4 MICROARRAYS
    • 8.4.1 WIDE ADOPTION OF MICROARRAYS IN CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH
    • TABLE 11 RNA ANALYSIS/TRANSCRIPTOMICS MICROARRAYS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 8.5 RNA INTERFERENCE (GENE SILENCING)
    • 8.5.1 TECHNOLOGICAL ADVANCEMENTS ARE SUPPORTING THE ADOPTION OF THIS TECHNIQUE FOR DIAGNOSTICS AND THERAPEUTICS
    • TABLE 12 RNA ANALYSIS/TRANSCRIPTOMICS RNA INTERFERENCE MARKET, BY COUNTRY, 2018-2025 (USD MILLION)

9 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 13 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • 9.2 DRUG DISCOVERY
    • 9.2.1 TARGETED SEQUENCING-BASED APPROACHES ARE GAINING MOMENTUM IN THE FIELD OF DRUG DISCOVERY
    • FIGURE 20 R&D INVESTMENTS IN LIFE SCIENCES, 2016-2018
    • TABLE 14 RNA ANALYSIS/TRANSCRIPTOMICS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2018-2025 (USD MILLION)
  • 9.3 CLINICAL DIAGNOSTICS
    • 9.3.1 TRANSCRIPTOMICS IS WIDELY ADOPTED FOR THE LARGE-SCALE GENE EXPRESSION PROFILING OF ONCOLOGICAL DISORDERS
    • TABLE 15 RNA ANALYSIS/TRANSCRIPTOMICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 9.4 TOXICOGENOMICS
    • 9.4.1 INCREASING FOCUS ON ADR STUDIES IS DRIVING THE ADOPTION OF TRANSCRIPTOMICS FOR SYSTEMIC TOXICOLOGY
    • TABLE 16 RNA ANALYSIS/TRANSCRIPTOMICS MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 9.5 COMPARATIVE TRANSCRIPTOMICS
    • 9.5.1 TRANSCRIPTIONAL PROFILES ARE BEING WIDELY ADOPTED TO STUDY THE EVOLUTION AMONG SPECIES
    • TABLE 17 RNA ANALYSIS/TRANSCRIPTOMICS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2018-2025 (USD MILLION)

10 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 18 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.2.1 INCREASING INVESTMENTS FOR ONCOLOGY THERAPEUTICS DRIVING THE USE OF OMICS TECHNOLOGIES
    • TABLE 19 RNA ANALYSIS/TRANSCRIPTOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2025 (USD MILLION)
  • 10.3 HOSPITALS & DIAGNOSTIC CENTERS
    • 10.3.1 USE OF WHOLE-BLOOD TRANSCRIPTOME PROFILES FOR DISEASE DIAGNOSTICS IS AIDING MARKET GROWTH
    • TABLE 20 RNA ANALYSIS/TRANSCRIPTOMICS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 10.4 ACADEMIC & RESEARCH INSTITUTES
    • 10.4.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL MARKET GROWTH
    • TABLE 21 RNA ANALYSIS/TRANSCRIPTOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2025 (USD MILLION)
  • 10.5 CONTRACT RESEARCH ORGANIZATIONS
    • 10.5.1 GROWING OUTSOURCING SERVICES BY PHARMACEUTICAL COMPANIES FOR FASTER DRUG DISCOVERY IS AIDING MARKET GROWTH
    • TABLE 22 RNA ANALYSIS/TRANSCRIPTOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2025 (USD MILLION)

11 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • FIGURE 21 RNA ANALYSIS/TRANSCRIPTOMICS MARKET: GEOGRAPHIC SNAPSHOT (2019)
    • TABLE 23 RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 22 NORTH AMERICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET SNAPSHOT
    • TABLE 24 NORTH AMERICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 25 NORTH AMERICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 26 NORTH AMERICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 27 NORTH AMERICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 28 NORTH AMERICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 The US dominates the North American market
    • TABLE 29 US: NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2019 VS. FY 2020 (USD BILLION)
    • TABLE 30 US: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 31 US: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 32 US: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 33 US: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Improving funding and infrastructure for omics-based research is supporting market growth
    • TABLE 34 CANADA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 35 CANADA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 36 CANADA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 37 CANADA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 11.3 EUROPE
    • FIGURE 23 EUROPE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET SNAPSHOT
    • TABLE 38 EUROPE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 39 EUROPE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 40 EUROPE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 41 EUROPE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 42 EUROPE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Germany holds the largest share of the European market
    • TABLE 43 GERMANY: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 44 GERMANY: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 45 GERMANY: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 46 GERMANY: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.3.2 FRANCE
      • 11.3.2.1 Increasing government support for omics-based research in the country to support market growth
    • TABLE 47 FRANCE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 48 FRANCE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 49 FRANCE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 50 FRANCE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.3.3 UK
      • 11.3.3.1 Rising public and private funding for research to drive market growth
    • TABLE 51 UK: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 52 UK: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 53 UK: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 54 UK: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Growth in this market is driven by the improving R&D expenditure and disease diagnostics
    • TABLE 55 ITALY: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 56 ITALY: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 57 ITALY: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 58 ITALY: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.3.5 SWITZERLAND
      • 11.3.5.1 Well-established pharmaceutical industry to drive market growth
    • TABLE 59 SWITZERLAND: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 60 SWITZERLAND: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 61 SWITZERLAND: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 62 SWITZERLAND: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.3.6 SPAIN
      • 11.3.6.1 Increasing collaborations for enhancing research to support market growth
    • TABLE 63 SPAIN: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 64 SPAIN: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 65 SPAIN: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 66 SPAIN: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 67 ROE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 68 ROE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 69 ROE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 70 ROE: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 24 ASIA PACIFIC: RNA ANALYSIS/TRANSCRIPTOMICS MARKET SNAPSHOT
    • TABLE 71 ASIA PACIFIC: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 72 ASIA PACIFIC: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 73 ASIA PACIFIC: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 74 ASIA PACIFIC: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 75 ASIA PACIFIC: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.4.1 JAPAN
      • 11.4.1.1 Early adoption of technologically advanced products to drive market growth
    • TABLE 76 JAPAN: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 77 JAPAN: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 78 JAPAN: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 79 JAPAN: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.4.2 CHINA
      • 11.4.2.1 China is one of the fastest-growing markets offering significant growth opportunities
    • TABLE 80 CHINA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 81 CHINA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 82 CHINA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 83 CHINA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Increasing pharmaceutical R&D spending and government funding for research to drive market growth
    • TABLE 84 INDIA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 85 INDIA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 86 INDIA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 87 INDIA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 11.4.4 REST OF ASIA PACIFIC
    • TABLE 88 ROAPAC: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 89 ROAPAC: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 90 ROAPAC: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 91 ROAPAC: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 11.5 LATIN AMERICA
    • 11.5.1 GROWTH IN THE PHARMACEUTICAL INDUSTRY IN MEXICO TO SUPPORT MARKET GROWTH
    • TABLE 92 LATIN AMERICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 93 LATIN AMERICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 94 LATIN AMERICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 95 LATIN AMERICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 IMPROVING FOCUS ON PRECISION MEDICINE AND DISEASE GENETICS IS DRIVING MARKET GROWTH
    • TABLE 96 MIDDLE EAST & AFRICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY PRODUCT & SERVICE, 2018-2025 (USD MILLION)
    • TABLE 97 MIDDLE EAST & AFRICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 98 MIDDLE EAST & AFRICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • TABLE 99 MIDDLE EAST & AFRICA: RNA ANALYSIS/TRANSCRIPTOMICS MARKET, BY END USER, 2018-2025 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
    • FIGURE 25 PRODUCT LAUNCHES-KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM JANUARY 2017 TO OCTOBER 2020
  • 12.2 MARKET SHARE ANALYSIS
    • FIGURE 26 NGS MARKET SHARE, BY KEY PLAYER, 2019
    • FIGURE 27 PCR MARKET SHARE, BY KEY PLAYER, 2019
  • 12.3 COMPANY EVALUATION MATRIX
    • 12.3.1 STARS
    • 12.3.2 EMERGING LEADERS
    • 12.3.3 PERVASIVE
    • 12.3.4 EMERGING COMPANIES
    • FIGURE 28 RNA ANALYSIS MARKET: COMPETITIVE LEADERSHIP MAPPING (2019)
  • 12.4 COMPETITIVE SITUATION AND TRENDS
    • 12.4.1 PRODUCT LAUNCHES
    • TABLE 100 PRODUCT LAUNCHES, 2017-2020
    • 12.4.2 EXPANSIONS
    • TABLE 101 EXPANSIONS, 2017-2020
    • 12.4.3 ACQUISITIONS
    • TABLE 102 ACQUISITIONS, 2017-2020
    • 12.4.4 OTHER STRATEGIES
    • TABLE 103 OTHER STRATEGIES, 2017-2020

13 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)**

  • 13.1 THERMO FISHER SCIENTIFIC, INC.
    • FIGURE 29 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019)
  • 13.2 AGILENT TECHNOLOGIES, INC.
    • FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2019)
  • 13.3 BIO-RAD LABORATORIES, INC.
    • FIGURE 31 BIO-RAD LABORATORIES, INC: COMPANY SNAPSHOT (2019)
  • 13.4 CD GENOMICS
  • 13.5 PROMEGA CORPORATION
  • 13.6 ILLUMINA, INC.
    • FIGURE 32 ILLUMINA, INC.: COMPANY SNAPSHOT (2019)
  • 13.7 QIAGEN N.V.
    • FIGURE 33 QIAGEN N.V.: COMPANY SNAPSHOT (2019)
  • 13.8 DANAHER CORPORATION
    • FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
  • 13.9 F. HOFFMANN-LA ROCHE LTD.
    • FIGURE 35 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2019)
  • 13.10 MERCK KGAA
    • FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT (2019)
  • 13.11 FLUIDIGM CORPORATION
    • FIGURE 37 FLUIDIGM CORPORATION: COMPANY SNAPSHOT (2019)
  • 13.12 EUROFINS SCIENTIFIC
    • FIGURE 38 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2019)
  • 13.13 SEQUENTIA BIOTECH SL
  • 13.14 ACOBIOM
  • 13.15 GENXPRO GMBH
  • 13.16 OTHER COMPANIES
    • 13.16.1 LEXOGEN GMBH
    • 13.16.2 CENIX BIOSCIENCE GMBH
    • 13.16.3 TAKARA HOLDINGS, INC.
    • 13.16.4 BIOMERIEUX SA
    • 13.16.5 LC SCIENCES, LLC

*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 INSIGHTS OF INDUSTRY EXPERTS
  • 14.2 DISCUSSION GUIDE
  • 14.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.4 AVAILABLE CUSTOMIZATIONS
  • 14.5 RELATED REPORTS
  • 14.6 AUTHOR DETAILS
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.